Uber Numb

Lidocaine Hydrochloride


Uberscientific, Llc
Human Otc Drug
NDC 71131-050
Uber Numb also known as Lidocaine Hydrochloride is a human otc drug labeled by 'Uberscientific, Llc'. National Drug Code (NDC) number for Uber Numb is 71131-050. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Uber Numb drug includes Lidocaine Hydrochloride - 50 mg/mL . The currest status of Uber Numb drug is Active.

Drug Information:

Drug NDC: 71131-050
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Uber Numb
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lidocaine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Uberscientific, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LIDOCAINE HYDROCHLORIDE - 50 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Nov, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 14 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:UBERScientific, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1545290
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0850777008002
UPC stands for Universal Product Code.
UNII:V13007Z41A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
71131-050-04118.29 mL in 1 BOTTLE, SPRAY (71131-050-04)01 Nov, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical anesthetic

Product Elements:

Uber numb lidocaine hydrochloride water propylene glycol sodium metabisulfite citric acid monohydrate epinephrine hydrochloride diazolidinyl urea methylparaben propylparaben edetate disodium anhydrous lidocaine hydrochloride lidocaine lidocaine

Indications and Usage:

Uses external use only. temporarily relieves pain, itching or swelling associated with anorectal disorders.

Warnings:

Warnings: keep out of reach of children. do not use if pregnant or breast feeding. for external use only, if accidentally ingested, seek meical attention immediately. do not use in large quantities, particularly over raw surfaces or blistered areas. avoid contact with the eyes, if contact with the eyes occur, rinse with copious amounts of eyewash and seek medical attention immediately. use on small area of skin to test for sensitivities prior to use. do not use if: you have a history of seizures. you have been diagnosed with liver disease. you have an allergy to any of the ingredients listed. if a reaction or sensitivity occurs, discontinue use and seek medical attention immediately. if condition worsens or symptoms are persistent for more than five days, or recur after clearing up, consult with a medical professional immediately.

Do Not Use:

Warnings: keep out of reach of children. do not use if pregnant or breast feeding. for external use only, if accidentally ingested, seek meical attention immediately. do not use in large quantities, particularly over raw surfaces or blistered areas. avoid contact with the eyes, if contact with the eyes occur, rinse with copious amounts of eyewash and seek medical attention immediately. use on small area of skin to test for sensitivities prior to use. do not use if: you have a history of seizures. you have been diagnosed with liver disease. you have an allergy to any of the ingredients listed. if a reaction or sensitivity occurs, discontinue use and seek medical attention immediately. if condition worsens or symptoms are persistent for more than five days, or recur after clearing up, consult with a medical professional immediately.

Dosage and Administration:

Directions: prior to using therapeutically, test on small area of skin for sensitivities and possible allergies, if adverse reaction occurs seek medical attention. spray ubernumb anesthetic spray, sparingly, on affected area. the area should begin to feel numbing anestehetic relief within two minutes. for continued numbing releif, reapply ubernumb sparingly as needed. if at any point, irritations or other sensitivities occur, discontinue use and seek medical attention store in a cool dark place or refrigerate. discard after expiration date

Package Label Principal Display Panel:

Package labeling: label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.